Subscribe to our Newsletters !!
It is incumbent on pharmaceutical and biopharmaceu
The pharmaceutical industry is currently experienc
The recent rabies death of an 11 year old Canadian
Zydus Lifesciences Limited (Zydus), in partnership
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Mi
Gilead Sciences Inc said on Friday additional data from a late-stage study revealed its antibacterial remdesivir significantly enhanced clinical recovery from seriously ill COVID-19 patients.
Findings from a study of its late-stage study revealed that 74.4 percent of remdesivir-treated patients recovered by Day 14 versus 59.0 percentage of individuals receiving standard of care, the business said.
Gilead shares were up almost 2 percent 76.14 prior to the bell.
